Phase I/II trial of sequential azacitidine and valproic acid plus carboplatin in the treatment of patients with advanced malignancies and platinum resistant epithelial ovarian cancer.

Trial Profile

Phase I/II trial of sequential azacitidine and valproic acid plus carboplatin in the treatment of patients with advanced malignancies and platinum resistant epithelial ovarian cancer.

Completed
Phase of Trial: Phase I/II

Latest Information Update: 29 Apr 2014

At a glance

  • Drugs Azacitidine (Primary) ; Azacitidine (Primary) ; Carboplatin (Primary) ; Valproic acid (Primary)
  • Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer; Solid tumours
  • Focus Adverse reactions; Biomarker; Pharmacogenomic; Therapeutic Use
  • Most Recent Events

    • 01 Oct 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 22 May 2012 Planned end date changed from 1 Aug 2013 to 1 Aug 2014 as reported by ClinicalTrials.gov.
    • 14 Nov 2011 Planned End Date changed from 1 Aug 2012 to 1 Aug 2013 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top